Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A multi-omics analysis identifies retinol metabolism in fibroblasts as a key pathway in wound healing

ABSTRACT: In this analysis, we assessed the subtle changes in retinol metabolism during wound healing, by analyzing the proteome of normal and wounded skin in Vitamin A deficient -treated mice using targeted proteomics,analysis, SureQuant.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Skin

DISEASE(S): Wounds And Injuries

SUBMITTER: Elizabeta Madzharova

LAB HEAD: Chiara Francavilla

PROVIDER: PXD061256 | Pride | 2025-10-03

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20230124_MK_EVO_EM_NoFAIMS_15cm_15SPD_skin_wt_ND_494.raw	Raw
	20230124_MK_EVO_EM_NoFAIMS_15cm_15SPD_skin_wt_ND_502.raw	Raw
	20230124_MK_EVO_EM_NoFAIMS_15cm_15SPD_skin_wt_VAD_505.raw	Raw
	20230124_MK_EVO_EM_NoFAIMS_15cm_15SPD_skin_wt_VAD_512.raw	Raw
	20230124_MK_EVO_EM_NoFAIMS_15cm_15SPD_wound_wt_ND_494.raw	Raw

Items per page:

1 - 5 of 24

Similar Datasets

Hybrid-DIA: Intelligent Data Acquisition for Simultaneous Targeted and Discovery Phosphoproteomics in Single Spheroids

Project description:Achieving sufficient coverage of regulatory phosphorylation sites by mass spectrometry (MS)-based phosphoproteomics for signaling pathway reconstitution is challenging when analyzing tiny sample amounts. We present a novel hybrid data-independent acquisition (DIA) strategy (hybrid-DIA) that combines targeted and discovery proteomics through an Application Programming Interface (API) to dynamically intercalate DIA scans with accurate triggering of multiplexed tandem MS scans of predefined (phospho)peptide targets. By spiking-in heavy stable isotope labeled phosphopeptide standards covering seven major signaling pathways, we benchmarked hybrid-DIA against state-of-the-art targeted MS methods (i.e. SureQuant) using EGF-stimulated HeLa cells and found the quantitative accuracy and sensitivity to be comparable while hybrid-DIA also profiled the global phosphoproteome. To demonstrate the robustness, sensitivity and potential of hybrid-DIA, we profiled chemotherapeutic agents in single colon carcinoma multicellular spheroids and evaluated the difference of cancer cells in 2D vs 3D culture. Altogether, we showed that hybrid-DIA is the way-to-go method in highly sensitive phospho-proteomics experiments.

2023-05-18 | PXD038947 | Pride

A multi-omics analysis identifies retinol metabolism in fibroblasts as a key pathway in wound healing

Project description:In this project, we analysed the proteome of skin wounds to investigate whether a vitamin A-deficient diet influences the wound proteome. To achieve this, we conducted quantitative, unbiased proteomic analysis using data-independent acquisition (DIA) mass spectrometr using skin wounds lysates.

2025-09-30 | PXD061167 | Pride

Immunopeptidomics reveals determinants of Mycobacterium tuberculosis antigen presentation on MHC class I (SureQuant data)

Project description:CD8+ T cells contribute to protective immunity to Mycobacterium tuberculosis (Mtb), but the principles that govern presentation of Mtb peptides on MHC class I (MHC-I) on the surface of infected macrophages for CD8+ T cell recognition are incompletely understood. Here, we use internal standard parallel reaction monitoring (IS-PRM, also known as SureQuant) to rigorously validate identifications of Mtb-derived MHC-I peptides obtained in data-dependent MS analyses. We further use SureQuant to quantify presentation of Mtb peptides derived from the secreted effector proteins EsxA and EsxJ across multiple experimental conditions. We show that presentation of both EsxA- and EsxJ-derived peptides requires the activity of the mycobacterial ESX-1 type VII secretion system, possibly indicating that ESX-1-mediated phagosome membrane damage allows Mtb proteins to access MHC-I antigen processing pathways. We show that this requirement is independent of type I interferon signaling that occurs downstream of phagosome damage. Treatment with inhibitors of conventional proteolytic pathways involved in MHC-I antigen processing inhibits presentation of self peptides as expected, but does not inhibit presentation of Mtb peptides, implying an alternative or redundant mechanism of processing.

2023-04-24 | PXD037843 | Pride

KiP analysis of ER+ Breast Cancer

Project description:Endocrine therapies (ET) combined with CDK4/6 inhibition (CDK4/6i) is standard treatment for estrogen receptor-α-positive (ER+) breast cancer, however lethal drug resistance is common. Proteogenomic analyses of 22 ER+ breast cancer patient-derived xenografts (PDXs) demonstrated that PKMYT1, a WEE1 homolog, is highly estradiol (E2) regulated in E2-dependent PDXs and constitutively expressed when growth is E2 independent. In clinical samples, high PKMYT1 mRNA is a resistance biomarker for both ET and CDK4/6 inhibition. The PKMYT1 inhibitor lunresertib(RP-6306) and gemcitabine selectively and synergistically reduced the viability of ET and palbociclib-resistant ER+ breast cancer cells without functional p53 in vitro; the combination increased DNA damage and apoptosis. In palbociclib-resistant, TP53 mutant PDX organoids and xenografts, RP-6306 with low-dose gemcitabine induced greater tumor volume reduction compared to treatment with either single agent. These results demonstrate the clinical potential of RP-6306 in combination with gemcitabine for ET and CDK4/6i resistant TP53 mutant ER+ breast cancer.

2025-05-13 | PXD050619 | Pride

Targeteted quantification of RORDEPs in fasting plasma of healthy adult men

Project description:In this study, we investigated two bacterially derived polypeptides, RORDEP1 and RORDEP2, previously identified in human plasma through data-independent acquisition (DIA) mass spectrometry. To accurately measure the concentrations of these peptides in fasting plasma samples obtained from 59 healthy adult men, we utilized a targeted mass spectrometry approach based on the SUREQuant method.

2025-06-04 | PXD057146 | Pride

Targeting kinome reprogramming in ESR1 fusion-driven breast cancer

Project description:Multiplexed, deep-scale LC-MSMS analysis for proteome and phosphoproteome expression profile and the targeted LC-MSMS analysis for kinases in enriched kinome of the ER+ breast cancer patient-derived xenograft tumors.

2023-10-24 | PXD036644 | Pride

Role of the Ccr4/Not complex in the regulation of heterochromatin in Schizosaccharomyces pombe (II)

Project description:RIP-chip experiments to identify RNAs associated with components of the Ccr4-Not complex in fission yeast

2015-09-25 | E-MTAB-3057 | biostudies-arrayexpress

Role of the Ccr4/Not complex in the regulation of heterochromatin in Schizosaccharomyces pombe (III)

Project description:RIP-chip experiments to identify RNAs associated with the Mmi1 protein in fission yeast

2015-09-25 | E-MTAB-3058 | biostudies-arrayexpress

Role of the Ccr4/Not complex in the regulation of heterochromatin in Schizosaccharomyces pombe (VI)

Project description:RIP-chip experiments to identify RNAs associated with components of the Ccr4-Not complex in fission yeast

2015-09-25 | E-MTAB-3065 | biostudies-arrayexpress

Immunopeptidomics informs discovery and delivery of Mycobacterium tuberculosis MHC-II antigens for vaccine design

Project description:No currently licensed vaccine reliably prevents pulmonary tuberculosis, a leading cause of infectious disease mortality with a growing rate of extensive drug resistance. Developing effective new vaccines will likely require identifying Mycobacterium tuberculosis (Mtb)-derived antigens presented on MHC class II (MHC-II) by infected phagocytes that CD4+ T cells can recognize to mediate protective immunity. To prime T cells capable of recognizing infected cells, vaccines will also need to deliver antigens to appropriate processing pathways. Here, we use mass spectrometry (MS) to identify 27 Mtb-derived MHC-II peptides presented by infected human dendritic cells, derived from 13 source proteins. Using targeted quantitative MS, we assess and optimize the ability of vaccines to drive presentation of MHC-II epitopes that match those presented by Mtb-infected cells, including the existing Bacillus Calmette Guerin (BCG) vaccine and new mRNA-encoded immunogens. Our results identify potential antigenic targets and immunogen design principles for tuberculosis vaccine development.

2025-09-18 | PXD055952 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data